Report overview
Genetically engineered human proteins play a crucial role in the market for therapeutic drugs.?Therapeutic proteins are essential for maintaining a healthy lifestyle and alleviating chronic disease.?They are necessary for people whose bodies cannot produce or break down certain essential proteins naturally.?Protein therapy plays an important role in the treatment of various cardiovascular diseases, such as heart failure, myocardial infarction, arrhythmia, coronary artery disease and ischemic heart disease.
This report contains market size and forecasts of Therapeutic Proteins for Cardiovascular Disorders Treatment in global, including the following market information:
Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Sales, 2017-2022, 2023-2028, (KG)
Global top five Therapeutic Proteins for Cardiovascular Disorders Treatment companies in 2021 (%)
The global Therapeutic Proteins for Cardiovascular Disorders Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Monoclonal Antibodies Proteins Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Therapeutic Proteins for Cardiovascular Disorders Treatment include Johnson & Johnson, Eli Lilly & Company, Roche, Pfizer, Bristol Myers Squibb, Sanofi, Merck, Amgen and Novartis and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Therapeutic Proteins for Cardiovascular Disorders Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (KG)
Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Segment Percentages, by Type, 2021 (%)
Monoclonal Antibodies Proteins
Peptides Proteins
Peptide Fragments Proteins
Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (KG)
Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Segment Percentages, by Application, 2021 (%)
Heart Failure
Myocardial Infarction
Arrhythmias
Coronary Artery Disease
Ischemic Heart Disease
Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (KG)
Global Therapeutic Proteins for Cardiovascular Disorders Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Therapeutic Proteins for Cardiovascular Disorders Treatment revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Therapeutic Proteins for Cardiovascular Disorders Treatment revenues share in global market, 2021 (%)
Key companies Therapeutic Proteins for Cardiovascular Disorders Treatment sales in global market, 2017-2022 (Estimated), (KG)
Key companies Therapeutic Proteins for Cardiovascular Disorders Treatment sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Johnson & Johnson
Eli Lilly & Company
Roche
Pfizer
Bristol Myers Squibb
Sanofi
Merck
Amgen
Novartis
Siemens Healthineers
